Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA-C2 + MVA-C
- Development stage
- Unknown
- Lead developer
- South African AIDS Vaccine Initiative
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DNA-C2 + MVA-C is a combination HIV-1 vaccine regimen that utilizes a heterologous prime-boost strategy. The regimen consists of two components: - **DNA-C2**: A plasmid DNA vaccine encoding HIV-1 subtype C antigens (including gag, pol, nef, and env genes). - **MVA-C**: A recombinant Modified Vaccinia Ankara (MVA) viral vector expressing the same or similar HIV-1 subtype C antigens. This combination is designed to induce robust cellular and humoral immune responses against HIV. The typical approach involves priming with the DNA vaccine (DNA-C2) followed by boosting with the viral vector vaccine (MVA-C). This strategy has been shown in preclinical and early clinical studies to enhance both CD4+ and CD8+ T cell responses as well as antibody production against HIV envelope proteins. The vaccines are based on clade C sequences relevant for regions where this subtype predominates[1][3][4][5].
- Other names
- SAAVI DNA-C2 + SAAVI MVA-C
02
Targets
Gag (HIV-1 Gag polyprotein)HIV-1 Pol polyprotein
Beyond the preview
Go deeper on DNA-C2 + MVA-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA-C2 + MVA-C.